



NIMH Report: New Approaches to using Brain Stimulation in Depression

Bruce Luber, Ph.D.

Staff Scientist

*Noninvasive Neuromodulation Unit
Experimental Therapeutics and Pathophysiology Branch
National Institute of Mental Health*



National Institute
of Mental Health



Outline of Talk

- Depression as a Brain Disorder
- Subconvulsive stimulation:
 - Transcranial Magnetic Stimulation (TMS) as a Treatment and Research Tool for Depression
 - CPAS Approach towards TMS Research in Depression
- Convulsive stimulation:
 - Magnetic Seizure Therapy (MST)
 - Individualized Low Amplitude Seizure Therapy (iLAST)

Treatment Resistant Depression is a major health problem

- Depression is a common mental disorder.
 - Globally, more than 300 million people of all ages suffer from depression.
 - -World Health Organization
- There is a great need for more effective treatments for depression:
 - For example, nearly one third of depressed patients achieve remission even after four consecutive trials of antidepressants
 - STAR*D trial, Warden et al., 2007
- Electromagnetic stimulation have proven their worth in treatment-resistant depression
 - Transcranial Magnetic Stimulation (TMS) was approved for use in treatment resistant depression in 2008
 - ECT remains the gold standard in treating depression

Transcranial Magnetic Stimulation (TMS)




- Very brief (< 1 ms) pulse of a large (1-2 Tesla) magnetic field
- Changing magnetic field induces current flow in cortex near the coil
- Currents are large enough to set off action potentials in neurons


TMS for Depression

- 2008: FDA Approved rTMS to treat Depression
- Though, like antidepressants, studies have shown modest effect sizes (15% remission, 30% response)

**HAMD24 Response Rate
(50% Improvement from Baseline)**



**HAMD24 Remission Rate
(HAMD24 Total Score <11)**



■ = Neurostar TMS Therapy ■ = Sham

Part of the reason for low efficacy in depression treatment may be in how TMS is targeted




Figure 1 Results of each subject's electrode positions relative to their left dorsolateral prefrontal cortex (DLPFC).

TMS is aimed at the dorsal lateral prefrontal cortex (DLPFC)

But its targeting is based on scalp localization:

- 5 cm rule

- 10/20 EEG System




In both cases, only approximately place TMS coil over the DLPFC target

Fitzgerald et al
Brain Stim 2009



There have been great advances in the tools to engage target brain networks

- Diffusion tensor imaging (DTI)
- fMRI and Resting State Connectivity
- Neuronavigation
- Electric field modeling
- Robotic coil holding
- Cortical targets
- Concurrent TMS/fMRI
- TMS/EEG (and soon, TMS/fMRI/EEG!)



And there has been a fundamental change in how we think about depression: Research Domain Criteria (RDoC)

Deconstructed, parsed, and diagnosed.

A hypothetical example illustrates how precision medicine might deconstruct traditional symptom-based categories. Patients with a range of mood disorders are studied across several analytical platforms to parse current heterogeneous syndromes into homogeneous clusters.

Symptom-based categories

Major depressive disorder



Mild depression
(dysthymia)



Bipolar depression



Integrated data

Genetic risk
polygenic risk score

Brain activity
insula cortex

Physiology
inflammatory markers

Behavioral process
affective bias

Life experience
social, cultural, and
environmental factors

Data-driven categories

Cluster 1



Cluster 2



Cluster 3



Cluster 4




Prospective
replication and
stratified clinical
trials

Taken from: Insel TR & Cuthbert BN. Brain Disorders? Precisely: Precision Medicine Comes to Psychiatry. Science. 2015 May 1;348(6234):499-500.

“Depression” Networks as Targets

Example of functional networks involved in depression:




Downar & Daskalakis, 2013



Can we use TMS to modulate abnormal activity in these brain networks?

Functional targeting: A novel tool to engage and modulate brain networks

- There is a huge source of variability in stimulation: the TMS pulse interacts with whatever activity is ongoing at the target
- But active contraction and imagery experiments in motor cortex show that controlling the state of the brain may be more effective



Synaptic coincidence: Hebbian plasticity





Further, activating the neurons in the target that are of interest gives them an edge for firing

Repeated pairings of local functional activity and TMS pulses may create a cumulative synaptic change along Hebbian lines

Most elementary form of functional targeting: Paired Associate Stimulation (PAS)

Long-lasting enhancements: creating long-term potentiation (LTP)/
long-term depression (LTD)-like plasticity effects

Paired Associated Stimulation (PAS)



PAS stimulation increases effectiveness
(accuracy in a motor task), in a cumulative
way

Generalizing PAS:

CPAS: Cognitive paired associate stimulation

Generalizing PAS in the motor cortex to any brain function and network suggests **Cognitive PAS (CPAS)**:

- a more active approach of **functional targeting**:
 - simultaneous activation of a network with noninvasive brain stimulation and behavioral performance



A paradigm for using CPAS in treating cognitive deficits:

- - a multi-modal approach to stimulation: concurrent TMS and task performance to enhance plasticity changes in targeted functions
- - repeated sessions to create a cumulative effect in those plasticity changes





An example of using the CPAS paradigm to remediate a cognitive deficit

Working Memory (WM) Task




In collaboration with
Yaakov Stern

First step: Demonstrate TMS enhancement of working memory



Site specific effect:
Parietal but not
DLPFC




Frequency specific
effect:
5 Hz rTMS during the
retention phase
reduced reaction
time (RT) for set size
1 and 6 ($p < 0.01$).



Task Phase specific effect:
With a new group ($N=22$),
5Hz to mPar reduced RT
only during retention
period

Second Step:

Demonstrate engagement of a brain network associated with a working memory deficit






Mapped network associated with resilience to sleep deprivation (N=15)

TMS to resilience targets during task



Site-specific enhancement found with TMS applied to lateral occipital cortex

Degree of improvement correlated with network expression

Third Step: Long-lasting prevention of memory deficit due to sleep deprivation



Post - Pre fMRI difference in RT between Active and Sham groups



5 Hz TMS+Task to lateral occipital cortex (LOC) (2/day x 2 days)
Prevented slowing and memory lapses **a full 18 hrs** after the last TMS


← Change in fMRI network localized under TMS coil

Currently applying to age-related WM deficits



Back to Depression: Imaging studies have mapped out “depression” networks to engage

Limbic-Cortical Dysregulation Model



One problem has been finding a “task” that activates this network

Social-cognitive systems for self-regulation: Regulatory Focus Theory

Promotion and prevention systems

Approach

Positive
Valence
System

Avoidance

Negative
Valence
System

At cortical level:

Promotion goals

Promotion: strategic bias toward
attaining positive end-states by
“making good things happen”

Disorder in promotion system:
possible pathway to
depression?

Prevention goals

Prevention: strategic bias toward
attaining positive end-states by
“keeping bad things from happening”

Prevention success leads to quiescence;
prevention failure is associated with
anxiety



Goal Priming Task




FIGURE 1 | Schematic of the experimental task, displaying a typical sequence of priming trials. The sequence for an individual trial consisted of alternating pound signs and percent signs, in between which a word or non-word was inserted. Promotion goal, prevention



goal, and yoked-control priming stimuli were inserted throughout the run. Incidental to those stimuli visible colored symbol stimuli were displayed to which participants were instructed to respond with a button press as quickly as possible.

Participants complete computerized version of the *Selves Questionnaire* (SQ; Higgins, Bond, Klein, & Strauman, 1986) sampling participants' own promotion and prevention goals


These promotion and prevention goal words are presented, along with control words subliminally during the task

3 runs, each 600 s long:
In each run, spaced around 18 s:
16 promotion words
16 prevention words
16 control words

Network associated with promotion/prevention




Signal change over time showing left prefrontal cortex (PFC) activation




Results from a Group (CTL, DEP) X Priming Type (promotion, prevention priming) conjunction analysis. From Detloff et al., (under review).

Prevention failure: Depressed pts with comorbid GAD showed *increased right PFC activation* following prevention priming:
Hyperactivation associated with vigilance and anxiety

Promotion failure: *decreased left PFC activation:*
Hypoactivation associated with dysphoria and anhedonia




Relationship of Promotion/Prevention imaging results with TMS depression paradigms



Disturbances in
Prevention goals
(comorbid anxiety) related
to hyperactivation

1 Hz (inhibitory) TMS to
right DLPFC effective



Disturbances on
Promotion goals
(depression) related to
hypoactivation

10 Hz (excitatory)
TMS to right DLPFC
effective

A CPAS-Based TMS depression treatment


- A depression-related network including cortical areas involved in emotional regulation, can be engaged
 - These regions include left and right prefrontal cortex regions where TMS has caused clinical response in depression, but which can be targeted with precision on an individual basis
- Functional targeting can be achieved by applying TMS simultaneously with talk therapy
 - For example, by using a structured, skill-based therapy for depression similar to cognitive therapy (CT) developed by Strauman et al.
 - This therapy has been shown to **affect the same DLPFC area as the fMRI targeting task:**
 - Baseline fMRI differences between med-free patients (N=10) and controls disappeared post therapeutic course (16 sessions): Strauman, Smith & Eddington, 2017



Pilot study: The CPAS approach to Depression


Pilot experiment (open label, 5 treatment-resistant MDD patients)

- Individualized targeting: left PFC promotion region activated in fMRI by priming task
- Plasticity component: simultaneous Self System Therapy (SST) with rTMS (standard parameters)






The CPAS approach to Depression

By 4 weeks, all 5 patients remitted



HAMD₁₇ total scores (A) and IDS Self report scores (B) for five patients suffering from major depressive episode, from the initial visit (T0), and at weekly follow-up assessments; tests administered before treatment.

Group analysis of pre/post fMRI differences showed changes in regions of the "Depression Network"



Functional activation changes from pre- to post-TMS course. Strongest effects are present in Ventro-medial PFC, a site of clear focus for targeted depression therapies. Warm colors: T2 > T1; cool colors: T1 > T2; results displayed at $p < 0.005$, uncorrected.

Neacsiu et al., in press

Graph-theoretical analysis showed a significant increase in fronto-temporal connectivity compared with healthy volunteers and patients who received only therapy

Davis et al., in revision




New TMS/therapy Study: A CPAS Approach to TMS Depression Treatment

- The CPAS approach- engaging specific brain networks associated with targeted psychological functions using functional neuroimaging, noninvasive brain stimulation, and functional targeting- may result in increased efficacy of neuropsychiatric treatment.
- We have begun a larger clinical trial to test our CPAS approach
 - comparing depressed individuals receiving either active or sham TMS
 - enrolling eligible adults ages 18-65 with major depressive disorder, who are free of other serious medical conditions.
 - If you are currently taking anti-depressants, you may still be eligible.
 - This inpatient and/or outpatient study involves daily visits for 8 weeks followed by once-monthly visits for 3 months.
 - for more information email moodresearch@mail.nih.gov or call 1-877-MIND-NIH (1-877-646-3644)



Convulsive Treatment of Depression: Magnetic Seizure Therapy (MST)



MST produces more localized, lower-intensity electrical stimulation in the brain

MST seizures are lower in amplitude compared to ECT






Figure 1




Cycowicz, Rowny, Lubner, Lisanby 2014 J ECT

Comparing ECT and MST head-to-head


- Table 1. Comparison of patient demographics between MST and ECT groups.

	Patient Group	
	<u>ECT</u>	<u>MST</u>
• N	37	34
• Mean Age	48.1 ± 13.0	47.7 ± 14.7
• Gender (M:F)	17:20	13:21
• Years of Education	15.5 ± 2.5	16.3 ± 3.2
• N, Uni- or Bi-polar	6	5
• Baseline HRSD	31.4 ± 7.3	29.7 ± 6.1
• Mean duration, current		
• Episode (weeks)	138 ± 150	134 ± 220


ECT and MST produced similar drops in depression severity



MST led to faster re-orientation and lower cognitive effects than ECT



Faster reorientation time following MST than ECT, with both threshold and suprathreshold treatments.




Improved verbal memory on the Rey Auditory and Verbal Learning Test (RAVLT) following MST compared to ECT.

Individualized Low Amplitude Seizure Therapy: Reinventing ECT

1 stimulus dosing



- § uses too high amplitude current
- § does not account for interindividual differences in head anatomy or cortical excitability




- § **current amplitude titration** coupled with **individual computation head model**
- § minimizes over-stimulation
- § reduces interindividual variability

2 spatial targeting




- § two large disc electrodes spaced wide apart
- § produces broad, nonfocal stimulation, contributing to side effects




- § **multi-electrode array** allows flexible and focal targeting of specific brain regions

3 seizure topography



- § two frontal EEG channels
- § no spatial information about the seizure




- § **high density ictal recording** allows discovery of optimal seizure propagation pattern

iLAST: First-in-human trial, Fall 2018


n = 10 completers

	Phase I: Baseline	Phase II: iLAST	Phase III: RUL ECT
Screening	Clinical & neurocognitive assessment with *video recording	Session 1-7: HD-RUL × 1, iECT-MC × 2, iECT-VX × 2, iECT-PFC × 2 (random order)	Standard course of RUL ECT + *full montage ictal EEG
Informed consent	Neuroimaging (MRI, DTI, *EEG-fMRI resting and task, *TMS-fMRI, *MEG) *Cortical excitability/plasticity assessment	Peri treatment assessment -Acute neurocog battery -Acute clinical assessment -*Video recording of neurocog/clinical assessment -resting EEG, *TMS-EP	Pre & Post acute course clinical/neurocog/ *neuroimaging/ *plasticity assessment Relapse prevention/maintenance

5 electrode adaptor



Next generation seizure therapy



- § multichannel stimulator (16 channels)
- § independent channel current control
- § prototyping Summer 2018

Pritchard & Deng, 2018

Conclusions

- New therapies for treatment resistant depression:
 - Non-convulsive: RDOC-based, fMRI-guided TMS
 - Individualized, based on engaging cortical circuitry involved in depression
 - Convulsive: MST and iLAST
 - Individualized, lower-intensity stimulation that induces therapeutic seizures but with less cognitive side effects
- Using the latest neuroscience to guide treatment development

Acknowledgments

ETPB Principal Investigators:

Holly Lisanby, M.D.

Carlos Zarate, M.D.

NIMH Associate Investigators and Staff Scientists:

Allison Nugent, Ph.D

Lawrence Park, M.D.

Wally Duncan, M.D.

Elizabeth Ballard, Ph.D.

Thomas Radman, Ph.D.

Zhi-De Deng, Ph.D.

Funding

NIMH

NIA

DARPA

Columbia University Collaborators:

Yaakov Stern

Paul Sajda

Dave Jangraw

Chris Habeck

Jason Steffener

Brian Rakitin

James Moeller

Teresa Nguyen

Peter Bulow

Duke University Collaborators:

Tim Strauman

Andrada Neacsiu

Simon Davis

Roberto Cabeza

Greg Appelbaum

Lysianne Beynel

David Murphy

Angel Peterchev

Lis Bernhardt

For more information email
moodresearch@mail.nih.gov
or call 1-877-MIND-NIH (1-
877-646-3644)

